{"id":584961,"date":"2026-06-22T14:56:04","date_gmt":"2026-06-22T14:56:04","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=584953"},"modified":"2026-07-09T09:03:49","modified_gmt":"2026-07-09T09:03:49","slug":"europe-looks-to-shore-up-global-competitiveness-with-the-e-u-biotech-act","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/blog\/europe-looks-to-shore-up-global-competitiveness-with-the-e-u-biotech-act\/","title":{"rendered":"EU Biotech Act\u306b\u3088\u308a\u3001\u6b27\u5dde\u306f\u30b0\u30ed\u30fc\u30d0\u30eb\u7af6\u4e89\u529b\u306e\u5f37\u5316\u3092\u76ee\u6307\u3059"},"content":{"rendered":"<p>\u6b27\u5dde\u306e\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u30fb\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306f\u8ee2\u63db\u70b9\u3092\u8fce\u3048\u3066\u3044\u307e\u3059\u3002EU Biotech Act\u306f\u5358\u306a\u308b\u898f\u5236\u6539\u9769\u3067\u306f\u3042\u308a\u307e\u305b\u3093\u3002\u904e\u53bb10\u5e74\u9593\u306b\u308f\u305f\u308b\u30b0\u30ed\u30fc\u30d0\u30eb\u7af6\u4e89\u529b\u306e\u4f4e\u4e0b\u306b\u5bfe\u3059\u308b\u6226\u7565\u7684\u306a\u5bfe\u5fdc\u3067\u3059\u3002<\/p>\n<p><a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/webinars\/is-the-eu-biotech-act-europes-innovation-turning-point\/\">our recent TOPRA webinar<\/a>\u3067\u3082\u8b70\u8ad6\u3057\u305f\u3088\u3046\u306b\u3001\u696d\u754c\u30ea\u30fc\u30c0\u30fc\u306b\u3068\u3063\u3066\u672c\u8cea\u7684\u306a\u554f\u3044\u306f\u3001\u3053\u306eAct\u304c\u91ce\u5fc3\u7684\u304b\u3069\u3046\u304b\u3067\u306f\u306a\u304f\u3001\u5b9f\u969b\u306b\u6295\u8cc7\u3092\u52d5\u304b\u3057\u3001\u958b\u767a\u3092\u52a0\u901f\u3057\u3001\u60a3\u8005\u30a2\u30af\u30bb\u30b9\u306e\u6210\u679c\u3092\u6539\u5584\u3067\u304d\u308b\u304b\u3069\u3046\u304b\u3067\u3059\u3002<\/p>\n<h3><strong>\u69cb\u9020\u7684\u306a\u7af6\u4e89\u529b\u306e\u554f\u984c\u2015\u2015\u3044\u307e\u3084\u8a8d\u8b58\u3055\u308c\u3066\u3044\u307e\u3059<\/strong><\/h3>\n<p>EU Biotech Act\u306e\u51fa\u767a\u70b9\u306f\u660e\u78ba\u3067\u3059\u3002\u6b27\u5dde\u306f\u5f8c\u308c\u3092\u53d6\u3063\u3066\u3044\u308b\u3068\u3044\u3046\u73fe\u5b9f\u3067\u3059\u3002<\/p>\n<ul>\n<li>\u6b27\u5dde\u304c\u4e16\u754c\u306e\u5546\u696d\u7684\u81e8\u5e8a\u8a66\u9a13\u306b\u5360\u3081\u308b\u5272\u5408\u306f\u3001\u904e\u53bb10\u5e74\u9593\u3067\u5927\u304d\u304f\u4f4e\u4e0b\u3057\u307e\u3057\u305f<\/li>\n<li>\u4e16\u754c\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u5411\u3051\u30d9\u30f3\u30c1\u30e3\u30fc\u30ad\u30e3\u30d4\u30bf\u30eb\u306e\u3046\u3061\u3001EU\u62e0\u70b9\u4f01\u696d\u306b\u6d41\u5165\u3059\u308b\u5272\u5408\u306f\u3054\u304f\u4e00\u90e8\u306b\u3068\u3069\u307e\u3063\u3066\u3044\u307e\u3059<\/li>\n<\/ul>\n<p>\u540c\u6642\u306b\u3001\u5730\u653f\u5b66\u7684\u306a\u6587\u8108\u3082\u5909\u5316\u3057\u3066\u3044\u307e\u3059\u3002\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u306f\u73fe\u5728\u3001AI\u3084\u91cf\u5b50\u6280\u8853\u3068\u4e26\u3073\u3001<strong>\u6226\u7565\u7684\u81ea\u5f8b\u6027<\/strong>\u3001\u7d4c\u6e08\u5b89\u5168\u4fdd\u969c\u3001\u7523\u696d\u30ec\u30b8\u30ea\u30a8\u30f3\u30b9\u3092\u652f\u3048\u308b\u67f1\u3068\u3057\u3066\u4f4d\u7f6e\u3065\u3051\u3089\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>Clarivate\u30a6\u30a7\u30d3\u30ca\u30fc\u306e\u8996\u70b9:<\/strong> \u3053\u308c\u306f\u6839\u672c\u7684\u306a\u518d\u4f4d\u7f6e\u3065\u3051\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002EU\u306f\u3082\u306f\u3084\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u3092\u500b\u5225\u30bb\u30af\u30bf\u30fc\u306e\u8ab2\u984c\u3068\u3057\u3066\u3067\u306f\u306a\u304f\u3001\u5c06\u6765\u306e\u7d4c\u6e08\u7684\u30ea\u30fc\u30c0\u30fc\u30b7\u30c3\u30d7\u3092\u652f\u3048\u308b\u4e2d\u6838\u30a4\u30f3\u30d5\u30e9\u3068\u3057\u3066\u6271\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<h3><strong>\u6469\u64e6\u304b\u3089\u6d41\u308c\u3078\uff1a\u771f\u306e\u30dc\u30c8\u30eb\u30cd\u30c3\u30af\u3078\u306e\u5bfe\u5fdc<\/strong><\/h3>\n<p>\u3053\u306eAct\u306e\u6700\u3082\u76f4\u63a5\u7684\u306a\u5f71\u97ff\u306f\u3001\u6b27\u5dde\u304c\u9577\u304f\u62b1\u3048\u3066\u304d\u305f\u5f31\u70b9\u306e\u4e00\u3064\u3001\u3059\u306a\u308f\u3061\u81e8\u5e8a\u958b\u767a\u306b\u304a\u3051\u308b\u904b\u7528\u4e0a\u306e\u5206\u65ad\u306b\u5bfe\u51e6\u3059\u308b\u70b9\u306b\u3042\u308a\u307e\u3059\u3002<br \/>\n\u4e3b\u306a\u63d0\u6848\u306b\u306f\u4ee5\u4e0b\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<ul>\n<li>\u591a\u56fd\u9593\u8a66\u9a13\u306e\u627f\u8a8d\u671f\u9593\u306e\u77ed\u7e2e\uff08\u7d0475\u65e5\u304b\u3089\u7d0447\u65e5\u3078\uff09<\/li>\n<li>\u91cd\u8907\u3092\u6e1b\u3089\u3059\u305f\u3081\u3001\u5358\u4e00\u306e\u300c\u5831\u544a\u52a0\u76df\u56fd\u300d\u306e\u5f79\u5272\u3092\u5f37\u5316\u3057\u307e\u3059<\/li>\n<li>\u8a66\u9a13\u5909\u66f4\u306b\u95a2\u3059\u308b\u30d7\u30ed\u30bb\u30b9\u3092\u4e26\u884c\u3057\u3066\u9032\u3081\u3089\u308c\u308b\u3088\u3046\u306b\u3057\u307e\u3059<\/li>\n<li>\u7533\u8acb\u3092\u52b9\u7387\u5316\u3059\u308b\u305f\u3081\u3001\u518d\u5229\u7528\u53ef\u80fd\u306a\u30b3\u30a2\u30c9\u30b7\u30a8\u3092\u5c0e\u5165\u3057\u307e\u3059<\/li>\n<\/ul>\n<p>\u73fe\u5728\u306e\u5b9f\u614b\u306f\u3001\u5358\u4e00\u306e\u8a66\u9a13\u304c\u52a0\u76df\u56fd\u3054\u3068\u306b\u5b9f\u8cea\u7684\u306b\u4f55\u5ea6\u3082\u518d\u8a55\u4fa1\u3055\u308c\u5f97\u308b\u4ed5\u7d44\u307f\u3067\u3042\u308a\u3001\u9045\u5ef6\u3001\u4e0d\u6574\u5408\u3001\u30b3\u30b9\u30c8\u52b9\u7387\u306e\u4f4e\u4e0b\u3092\u751f\u3093\u3067\u3044\u307e\u3059\u3002<\/p>\n<p>\u3053\u306eAct\u306f\u3001\u3053\u308c\u3092<strong>\u76f8\u4e92\u4fe1\u983c\u3068\u5354\u8abf\u7684\u5be9\u67fb<\/strong>\u306b\u57fa\u3065\u304f\u30e2\u30c7\u30eb\u3078\u7f6e\u304d\u63db\u3048\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p><strong>Clarivate\u30a6\u30a7\u30d3\u30ca\u30fc\u306e\u8996\u70b9\uff1a<\/strong>\u5b8c\u5168\u306b\u904b\u7528\u3055\u308c\u308c\u3070\u3001\u6b27\u5dde\u3068\u7c73\u56fd\u30fb\u4e2d\u56fd\u672c\u571f\u306e\u3088\u3046\u306a\u3088\u308a\u6a5f\u52d5\u7684\u306a\u5e02\u5834\u3068\u306e\u5b9f\u884c\u529b\u306e\u5dee\u3092\u5927\u304d\u304f\u7e2e\u3081\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u305f\u3060\u3057\u3001\u904e\u53bb\u306e\u4e8b\u4f8b\u304b\u3089\u306f\u3001\u898f\u5236\u4e0a\u306e\u610f\u56f3\u3068\u73fe\u5834\u3067\u306e\u7d4c\u9a13\u304c\u5927\u304d\u304f\u4e56\u96e2\u3057\u5f97\u308b\u3053\u3068\u3082\u793a\u5506\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n<h3><strong>\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306e\u4ed5\u7d44\u307f\uff1a\u671f\u5f85\u306f\u3042\u308b\u3082\u306e\u306e\u3001\u5341\u5206\u306b\u306f\u5b9a\u7fa9\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong><\/h3>\n<ul>\u52b9\u7387\u5316\u306b\u52a0\u3048\u3066\u3001\u3053\u306eAct\u306f\u6b21\u4e16\u4ee3\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3092\u52a0\u901f\u3059\u308b\u305f\u3081\u306e\u65b0\u305f\u306a\u30c4\u30fc\u30eb\u30ad\u30c3\u30c8\u3092\u5c0e\u5165\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<li>\u898f\u5236\u30b5\u30f3\u30c9\u30dc\u30c3\u30af\u30b9\uff1aAI\u3084\u5148\u9032\u6cbb\u7642\u306a\u3069\u306e\u65b0\u8208\u6280\u8853\u306b\u5bfe\u3059\u308b\u7ba1\u7406\u3055\u308c\u305f\u8a66\u9a13\u74b0\u5883<\/li>\n<li>\u958b\u767a\u304a\u3088\u3073\u898f\u5236\u30d7\u30ed\u30bb\u30b9\u5168\u4f53\u306b\u304a\u3051\u308bAI\u7d71\u5408\u306e\u62e1\u5927<\/li>\n<li>\u6295\u8cc7\u3092\u547c\u3073\u8fbc\u3080\u305f\u3081\u306e\u5b98\u6c11\u8cc7\u91d1\u30e2\u30c7\u30eb<\/li>\n<li>\u30d0\u30a4\u30aa\u30c6\u30c3\u30afSME\u304a\u3088\u3073\u30b9\u30b1\u30fc\u30eb\u30a2\u30c3\u30d7\u4f01\u696d\u5411\u3051\u306e\u652f\u63f4\u30a4\u30f3\u30d5\u30e9<\/li>\n<\/ul>\n<p>\u3053\u308c\u3089\u306e\u4ed5\u7d44\u307f\u306f\u3001\u3088\u308a\u9069\u5fdc\u7684\u3067\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306b\u89aa\u548c\u7684\u306a\u898f\u5236\u3078\u306e\u8ee2\u63db\u3092\u53cd\u6620\u3057\u3066\u3044\u307e\u3059\u3002\u305f\u3060\u3057\u3001\u305d\u306e\u5b9f\u7528\u5316\u306f\u307e\u3060\u521d\u671f\u6bb5\u968e\u306b\u3042\u308a\u307e\u3059\u3002<\/p>\n<p><strong>Clarivate\u30a6\u30a7\u30d3\u30ca\u30fc\u306e\u8996\u70b9\uff1a<\/strong>\u6a5f\u4f1a\u306f\u78ba\u304b\u306b\u5b58\u5728\u3057\u307e\u3059\u304c\u3001\u307e\u3060\u65e9\u671f\u6bb5\u968e\u3067\u3059\u3002\u30d1\u30a4\u30ed\u30c3\u30c8\u306b\u7a4d\u6975\u7684\u306b\u95a2\u4e0e\u3057\u3001\u5b9f\u88c5\u306e\u5f62\u3065\u304f\u308a\u306b\u53c2\u52a0\u3059\u308b\u4f01\u696d\u306f\u3001\u898f\u5236\u4e0a\u306e\u660e\u78ba\u5316\u3092\u5f85\u3064\u4f01\u696d\u3088\u308a\u3082\u512a\u4f4d\u306b\u7acb\u3064\u3067\u3057\u3087\u3046\u3002<\/p>\n<h3><strong>\u30a4\u30f3\u30bb\u30f3\u30c6\u30a3\u30d6\uff1a\u5fc5\u8981\u3067\u306f\u3042\u308b\u3082\u306e\u306e\u3001\u307e\u3060\u5341\u5206\u3067\u306f\u3042\u308a\u307e\u305b\u3093<\/strong><\/h3>\n<p>\u7d4c\u55b6\u5c64\u306b\u3068\u3063\u3066\u4e2d\u5fc3\u7684\u306a\u554f\u3044\u306f\u3001EU\u304c\u6295\u8cc7\u3092\u547c\u3073\u8fbc\u3080\u306e\u306b\u5341\u5206\u7af6\u4e89\u529b\u306e\u3042\u308b\u74b0\u5883\u3092\u4f5c\u308a\u51fa\u3057\u3066\u3044\u308b\u304b\u3069\u3046\u304b\u3067\u3059\u3002<br \/>\n\u4e3b\u8981\u306a\u30a4\u30f3\u30bb\u30f3\u30c6\u30a3\u30d6\u3067\u3042\u308b\u88dc\u5145\u7684\u4fdd\u8b77\u8a3c\u660e\u66f8\uff08SPC\uff09\u306e12\u304b\u6708\u5ef6\u9577\u306f\u3001\u65b9\u5411\u6027\u3068\u3057\u3066\u306f\u524d\u5411\u304d\u3067\u3059\u304c\u3001\u6761\u4ef6\u4ed8\u304d\u3067\u3059\u3002<\/p>\n<ul>\n<li>EU\u306b\u304a\u3051\u308b\u591a\u56fd\u9593\u8a66\u9a13\u304c\u5fc5\u8981\u3067\u3059<\/li>\n<li>EU\u5185\u306b\u88fd\u9020\u62e0\u70b9\u3092\u6709\u3059\u308b\u3053\u3068\u304c\u5fc5\u8981\u3067\u3059<\/li>\n<li>\u65b0\u898f\u4f5c\u7528\u6a5f\u5e8f\u306e\u57fa\u6e96\u304c\u9069\u7528\u3055\u308c\u307e\u3059<\/li>\n<\/ul>\n<p>\u3053\u308c\u3089\u306f\u610f\u5473\u306e\u3042\u308b\u3082\u306e\u3067\u3059\u304c\u3001\u7c73\u56fd\u3084\u65b0\u8208\u306e\u30a2\u30b8\u30a2\u62e0\u70b9\u304c\u63d0\u4f9b\u3059\u308b\u30a4\u30f3\u30bb\u30f3\u30c6\u30a3\u30d6\u3068\u6bd4\u3079\u308b\u3068\u3001\u306a\u304a\u898b\u52a3\u308a\u3059\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002<\/p>\n<p><strong>Clarivate\u30a6\u30a7\u30d3\u30ca\u30fc\u306e\u8996\u70b9\uff1a<\/strong> EU\u306f\u610f\u601d\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002\u3057\u304b\u3057\u3001\u6295\u8cc7\u5224\u65ad\u3068\u3057\u3066\u306e\u8aac\u5f97\u529b\u306f\u3001\u6700\u7d42\u7684\u306a\u5b9f\u88c5\u3068\u3001\u30a4\u30f3\u30bb\u30f3\u30c6\u30a3\u30d6\u3068\u904b\u7528\u4e0a\u306e\u8907\u96d1\u3055\u306e\u30d0\u30e9\u30f3\u30b9\u306b\u5de6\u53f3\u3055\u308c\u307e\u3059\u3002<\/p>\n<h3><strong>\u6226\u7565\u7684\u8ee2\u63db\uff1a\u30c7\u30fc\u30bf\u3068\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u30a8\u30f3\u30b8\u30f3\u3068\u3057\u3066\u306e\u6b27\u5dde<\/strong><\/h3>\n<p>\u304a\u305d\u3089\u304f\u6700\u3082\u898b\u904e\u3054\u3055\u308c\u304c\u3061\u306a\u5909\u5316\u306f\u3001\u3053\u306eAct\u304c<strong>\u6b27\u5dde\u5185\u3067\u306e\u30a8\u30d3\u30c7\u30f3\u30b9\u5275\u51fa\u306e\u5b9a\u7740<\/strong>\u306b\u7126\u70b9\u3092\u5f53\u3066\u3066\u3044\u308b\u70b9\u3067\u3059\u3002<br \/>\n\u5177\u4f53\u7684\u306b\u306f\u3001\u4ee5\u4e0b\u3092\u901a\u3058\u3066\u5b9f\u73fe\u3092\u76ee\u6307\u3057\u307e\u3059\u3002<\/p>\n<ul>\n<li>EU\u96c6\u56e3\u3092\u5bfe\u8c61\u3068\u3059\u308b\u81e8\u5e8a\u8a66\u9a13\u3092\u5897\u3084\u3057\u307e\u3059<\/li>\n<li>\u958b\u767a\u3092EU\u306eHTA\u304a\u3088\u3073\u898f\u5236\u8981\u4ef6\u3068\u6574\u5408\u3055\u305b\u307e\u3059<\/li>\n<li>\u6bd4\u8f03\u30a8\u30d3\u30c7\u30f3\u30b9\u304a\u3088\u3073\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u5275\u51fa\u3092\u652f\u63f4\u3057\u307e\u3059<\/li>\n<\/ul>\n<p>\u3053\u308c\u306b\u3088\u308a\u3001\u3053\u306eAct\u306f\u6b27\u5dde\u3092\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u306e\u62e0\u70b9\u3067\u3042\u308b\u3060\u3051\u3067\u306a\u304f\u3001<strong>\u610f\u601d\u6c7a\u5b9a\u306b\u8cc7\u3059\u308b\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u62e0\u70b9<\/strong>\u3068\u3057\u3066\u518d\u4f4d\u7f6e\u3065\u3051\u308b\u3053\u3068\u3092\u76ee\u6307\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>\u3053\u308c\u306f\u3001Joint Clinical Assessments\uff08JCAs\uff09\u3084\u3088\u308a\u5e83\u7bc4\u306a\u533b\u85ac\u54c1\u5236\u5ea6\u6539\u9769\u306b\u3088\u3063\u3066\u3001\u4fa1\u5024\u8a3c\u660e\u3078\u306e\u7cbe\u67fb\u304c\u5f37\u307e\u308b\u4e2d\u3067\u7279\u306b\u91cd\u8981\u3067\u3059\u3002<\/p>\n<p><strong>Clarivate\u306e\u30a4\u30f3\u30b5\u30a4\u30c8\uff1a<\/strong>\u7af6\u4e89\u512a\u4f4d\u6027\u306f\u4eca\u5f8c\u3001\u65e9\u671f\u306b\u9069\u5207\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u6226\u7565\u3092\u69cb\u7bc9\u3067\u304d\u308b\u304b\u306b\u307e\u3059\u307e\u3059\u5de6\u53f3\u3055\u308c\u307e\u3059\u3002\u3059\u306a\u308f\u3061\u3001\u898f\u5236\u3001HTA\u3001\u652f\u6255\u8005\u306e\u8981\u4ef6\u3092\u521d\u671f\u6bb5\u968e\u304b\u3089\u7d71\u5408\u3059\u308b\u3053\u3068\u304c\u91cd\u8981\u3067\u3059\u3002<\/p>\n<h3><strong>\u5b9f\u884c\u30ae\u30e3\u30c3\u30d7\uff1a\u6210\u679c\u3092\u5de6\u53f3\u3059\u308b\u30dd\u30a4\u30f3\u30c8<\/strong><\/h3>\n<p>EU Biotech Act\u306f\u3001\u898f\u5236\u3001\u30a4\u30ce\u30d9\u30fc\u30b7\u30e7\u30f3\u3001\u30a2\u30af\u30bb\u30b9\u3092\u4e00\u8cab\u3057\u305f\u30a8\u30b3\u30b7\u30b9\u30c6\u30e0\u3068\u3057\u3066\u6574\u5408\u3055\u305b\u3088\u3046\u3068\u3059\u308b\u3001\u975e\u5e38\u306b\u91ce\u5fc3\u7684\u306a\u53d6\u308a\u7d44\u307f\u3067\u3059\u3002<\/p>\n<p>\u305f\u3060\u3057\u30013\u3064\u306e\u30ea\u30b9\u30af\u304c\u6b8b\u308a\u307e\u3059\u3002<\/p>\n<ol>\n<li>\u5b9f\u88c5\u306e\u8907\u96d1\u3055\uff1a\u533b\u85ac\u54c1\u30d1\u30c3\u30b1\u30fc\u30b8\u3001JCA\u3001\u533b\u7642\u6a5f\u5668\u898f\u5236\u306a\u3069\u8907\u6570\u306e\u6539\u9769\u304c\u540c\u6642\u306b\u9032\u884c\u3059\u308b\u305f\u3081\u3067\u3059<\/li>\n<li>\u4e3b\u8981\u6761\u9805\u304c\u5e0c\u8584\u5316\u3059\u308b\u53ef\u80fd\u6027\uff1a\u7acb\u6cd5\u30d7\u30ed\u30bb\u30b9\u306e\u4e2d\u3067\u8d77\u3053\u308a\u5f97\u307e\u3059<\/li>\n<li>\u904b\u7528\u4e0a\u306e\u73fe\u5b9f\uff1a\u52a0\u76df\u56fd\u9593\u306e\u30ea\u30bd\u30fc\u30b9\u3001IT\u30a4\u30f3\u30d5\u30e9\u3001\u6587\u5316\u7684\u5909\u5316\u306a\u3069\u304c\u542b\u307e\u308c\u307e\u3059<\/li>\n<\/ol>\n<p>\u6700\u7d42\u7684\u306a\u6210\u529f\u306f\u3001\u30b7\u30b9\u30c6\u30e0\u304c\u771f\u306b\u4ee5\u4e0b\u306e\u65b9\u5411\u3078\u79fb\u884c\u3067\u304d\u308b\u304b\u3069\u3046\u304b\u306b\u304b\u304b\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n<ul>\n<li>\u3088\u308a\u8fc5\u901f\u306a\u610f\u601d\u6c7a\u5b9a<\/li>\n<li>\u76f8\u4e92\u4f9d\u62e0\u306e\u5f37\u5316<\/li>\n<li>\u30a4\u30ce\u30d9\u30fc\u30bf\u30fc\u306b\u3068\u3063\u3066\u3088\u308a\u4e88\u6e2c\u53ef\u80fd\u306a\u9053\u7b4b<\/li>\n<\/ul>\n<h3><strong>\u7d4c\u55b6\u5c64\u304c\u4eca\u3059\u3079\u304d\u3053\u3068<\/strong><\/h3>\n<ol>\n<li><strong>\u5b9f\u88c5\u306e\u5f62\u3065\u304f\u308a\u306b\u65e9\u671f\u304b\u3089\u95a2\u4e0e\u3057\u307e\u3059<\/strong><br \/>\n\u898f\u5236\u30b5\u30f3\u30c9\u30dc\u30c3\u30af\u30b9\u3001\u30d1\u30a4\u30ed\u30c3\u30c8\uff08\u4f8b\uff1a\u8fc5\u901f\u5316\u3055\u308c\u305f\u8a66\u9a13\u30a4\u30cb\u30b7\u30a2\u30c1\u30d6\uff09\u3001\u30b9\u30c6\u30fc\u30af\u30db\u30eb\u30c0\u30fc\u5354\u8b70\u304c\u3001\u3053\u306eAct\u306e\u5b9f\u52d9\u4e0a\u306e\u6a5f\u80fd\u3092\u5b9a\u7fa9\u3057\u3066\u3044\u304d\u307e\u3059\u3002<\/li>\n<li><strong>EU\u958b\u767a\u6226\u7565\u3092\u518d\u8abf\u6574\u3057\u307e\u3059<\/strong><br \/>\n\u6b27\u5dde\u3067\u306e\u30a2\u30af\u30bb\u30b9\u8981\u4ef6\u3092\u521d\u65e5\u304b\u3089\u7d44\u307f\u8fbc\u3093\u3060\u8a66\u9a13\u8a2d\u8a08\u3068\u30a8\u30d3\u30c7\u30f3\u30b9\u5275\u51fa\u8a08\u753b\u3092\u7b56\u5b9a\u3057\u307e\u3059\u3002<\/li>\n<li><strong>\u30a4\u30f3\u30bb\u30f3\u30c6\u30a3\u30d6\u3068\u7acb\u6cd5\u52d5\u5411\u3092\u7dbf\u5bc6\u306b\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\u3057\u307e\u3059<\/strong><br \/>\nSPC\u3001\u8cc7\u91d1\u8abf\u9054\u624b\u6bb5\u3001\u904b\u7528\u30eb\u30fc\u30eb\u306b\u95a2\u3059\u308b\u6700\u7d42\u7684\u306a\u8a73\u7d30\u306f\u3001\u6295\u8cc7\u5224\u65ad\u306b\u5927\u304d\u306a\u5f71\u97ff\u3092\u4e0e\u3048\u307e\u3059\u3002<\/li>\n<\/ol>\n<h3><strong>\u7d50\u8ad6<\/strong><\/h3>\n<p>EU Biotech Act\u306f\u3001\u6025\u901f\u306b\u5909\u5316\u3059\u308b\u4e16\u754c\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u74b0\u5883\u306e\u4e2d\u3067\u6b27\u5dde\u3092\u518d\u4f4d\u7f6e\u3065\u3051\u308b\u305f\u3081\u306e\u3001\u4fe1\u983c\u306b\u8db3\u308b\u8a66\u307f\u3067\u3059\u3002<br \/>\n\u3057\u304b\u3057\u3001\u6cd5\u5f8b\u3060\u3051\u3067\u7af6\u4e89\u529b\u306e\u30ae\u30e3\u30c3\u30d7\u3092\u57cb\u3081\u308b\u3053\u3068\u306f\u3067\u304d\u307e\u305b\u3093\u3002<br \/>\n<strong>\u305d\u308c\u3092\u5b9f\u73fe\u3059\u308b\u306e\u306f\u5b9f\u884c\u529b\u3067\u3059\u3002<\/strong><\/p>\n<p>\u696d\u754c\u30ea\u30fc\u30c0\u30fc\u306b\u3068\u3063\u3066\u306e\u8981\u8acb\u306f\u660e\u78ba\u3067\u3059\u3002\u53d7\u3051\u8eab\u306e\u89b3\u5bdf\u304b\u3089\u80fd\u52d5\u7684\u306a\u53c2\u753b\u3078\u79fb\u884c\u3059\u308b\u3053\u3068\u3067\u3059\u3002\u306a\u305c\u306a\u3089\u3001\u5236\u5ea6\u3065\u304f\u308a\u306b\u95a2\u4e0e\u3059\u308b\u4f01\u696d\u3053\u305d\u304c\u3001\u305d\u306e\u6069\u6075\u3092\u53d7\u3051\u308b\u3046\u3048\u3067\u6700\u3082\u6709\u5229\u306a\u7acb\u5834\u306b\u7acb\u3064\u304b\u3089\u3067\u3059\u3002<\/p>\n<p><strong>\u30a6\u30a7\u30d3\u30ca\u30fc\u306f\u3053\u3061\u3089\u304b\u3089\u3054\u89a7\u304f\u3060\u3055\u3044\uff1a <\/strong><a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/webinars\/is-the-eu-biotech-act-europes-innovation-turning-point\/\"><strong>Is the EU Biotech Act Europe\u2019s innovation turning point? | Clarivate<\/strong><\/a><\/p>\n<p><em><strong>\u88fd\u54c1\u30e9\u30a4\u30d5\u30b5\u30a4\u30af\u30eb\u5168\u4f53\u306b\u308f\u305f\u308b\u00a0<\/strong><a href=\"https:\/\/clarivate.com\/life-sciences-healthcare\/ja\/lp\/cortellis-regulatory-intelligence\/\"><strong>\u30b0\u30ed\u30fc\u30d0\u30eb\u898f\u5236\u30a4\u30f3\u30c6\u30ea\u30b8\u30a7\u30f3\u30b9<\/strong><\/a><strong>\u304c\u3001\u5341\u5206\u306a\u60c5\u5831\u306b\u57fa\u3065\u304f\u898f\u5236\u95a2\u9023\u306e\u610f\u601d\u6c7a\u5b9a\u3092\u3069\u306e\u3088\u3046\u306b\u652f\u63f4\u3059\u308b\u304b\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002<\/strong><\/em><br \/>\n\u203b\u672c\u8a18\u4e8b\u306fClarivate.com\u306e\u82f1\u8a9e\u539f\u6587\u3092AI\u7ffb\u8a33\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u30af\u30e9\u30ea\u30d9\u30a4\u30c8\u306e\u30a4\u30f3\u30b5\u30a4\u30c8\u3092\u3082\u3068\u306b\u3001EU Biotech Act\u304c\u6b27\u5dde\u306e\u30d0\u30a4\u30aa\u30c6\u30c3\u30af\u30fb\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u696d\u754c\u306b\u3082\u305f\u3089\u3059\u5f71\u97ff\u3092\u89e3\u8aac\u3057\u307e\u3059\u3002<\/p>\n","protected":false},"author":141,"featured_media":584954,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[1309],"tags":[1086,2597,2636,2703,2981,2984,2987,2639,2603,2990,1120,2803],"class_list":["post-584961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biopharma","tag-biopharma","tag-biotech","tag-business-development","tag-clinical-trials","tag-ema","tag-emea","tag-europe","tag-market-access-2","tag-pharma","tag-policy","tag-regulatory-ja","tag-research","clarivate-product-biopharma"],"acf":[],"lang":"ja","translations":{"ja":584961,"en":584953,"ko":584962},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/584961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/141"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=584961"}],"version-history":[{"count":5,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/584961\/revisions"}],"predecessor-version":[{"id":585909,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/584961\/revisions\/585909"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/584954"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=584961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=584961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=584961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}